Citius Pharmaceuticals 주식 (NASDAQ: CTXR)

에 대한 최신 뉴스 Citius Pharmaceuticals (NASDAQ:CTXR) 주식

Citius Pharmaceuticals

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.

News

Pre-Market Outlook

Markets

Trading Ideas

$LUNA

CCTG

CTXR

LUNA

월요일(30일) 아침 미국 주식 선물이 하락한 가운데, 오늘 투자자들의 관심을 끌 수 있는 종목은 다음과 같다. 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 파마슈티컬스 및 지니어스 그룹

월요일 주목해야 할 주식: 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 및 지니어스 그룹

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

RBC Capital analyst Kenneth Lee reiterates Acadian Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAMI#NYSE">AAMI</a>) with a Sector Perform and maintains $27 price target.

Price Target

Reiteration

Analyst Ratings

AAMI

RBC Capital Reiterates Sector Perform on Acadian Asset Management, Maintains $27 Price Target

Evercore ISI Group analyst Durgesh Chopra maintains Montrose Environmental Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEG#NYSE">MEG</a>) with a Outperform and lowers the price target from $40 to $33.

Evercore ISI Group Maintains Outperform on Montrose Environmental Gr, Lowers Price Target to $33

Last week was <a href="https://www.benzinga.com/25/02/43574339/magnificent-seven-slip-inflation-fears-grip-consumers-gold-hits-record-highs">another power-packed one</a>. Wall Street faced volatility as tech earnings disappointed, labor data signaled mixed trends, and inflation fears grew amid rising tariffs. Gold hit record highs as a safe haven, while geopolitical tensions and Ford's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) weak EV outlook added to market uncertainty. Amid these dynamics, we identified <a href="https://www.benzinga.com/etfs">five ETFs </a>that braved the volatility and posted gains:
Direxion Daily PLTR Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTU#NASDAQ">PLTU</a>)
<ul>
<li>Weekly gain:&nbsp;78.82%</li>
<li>Focus: Leveraged equity ETF that seeks to track 200% of the performance of Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>).</li>
<li>Expense ratio:&nbsp;0.99%</li>
</ul>
AdvisorShares Psychedelics ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSIL#NYSE">PSIL</a>)
<ul>
<li>Weekly gain:&nbsp;21.61%</li>
<li>Focus:&nbsp;Primarily invests in life sciences companies focused on psychedelic medicines as well as other companies with business in the psychedelics space. </li>
<li>Expense ratio:&nbsp;1.01%</li>
</ul>
United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>)
<ul>
<li>Weekly gain:&nbsp;10.84%</li>
<li>Focus:&nbsp;Tracks the daily price movements of natural gas. This ETF mainly invests in natural gas futures contracts.</li>
<li>Expense ratio:&nbsp;1.01%</li>
</ul>
Roundhill Video Games ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERD#NASDAQ">NERD</a>) 
<ul>
<li>Weekly gain:&nbsp;4.75%</li>
<li>Focus:&nbsp;Follows the Nasdaq CTA Global Video Games Software Index. Names like Nintendo, Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) and Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) are included in this passively managed ETF&#8217;s portfolio.</li>
<li>Expense ratio:&nbsp;0.50%</li>
</ul>
Defiance Connective Technologies ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIXG#NASDAQ">SIXG</a>)
<ul>
<li>Weekly gain:&nbsp;4.58%</li>
<li>Focus: Tracks the BlueStar Connective Technologies Index that follows the performance of U.S.-listed companies in the hardware, software, or services related to 5G, or 6G networks, and other connective technologies.</li>
<li>Expense ratio:&nbsp;0.30%</li>
</ul>
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43594031/t-mobile-stock-is-rising-monday-whats-going-on">T-Mobile Stock Is Rising Monday: What&#8217;s Going On?</a>
What Drove Markets Last Week
Beginning with the mega-cap tech earnings last week, companies including Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), fell short of lofty expectations, weighing on markets despite support from Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and financial sector stocks. 
On the economic front, January's job report was a mixed bag. Nonfarm payrolls rose just 143,000—far below December's 307,000 and short of economists' 170,000 estimate. Yet, the unemployment rate dipped, and wages climbed faster than expected.
A warning sign popped up Friday when the University of Michigan's consumer sentiment index unexpectedly dropped. The survey showed consumer sentiment falling to 67.8, with inflation expectations rising to 4.3%—the highest since late 2023. The report linked this unease to higher tariffs under the Trump administration.
Gold surged to record highs, topping $2,850 per ounce, as investors sought safety amid inflation worries and policy uncertainty. This marks its sixth straight week of gains, reinforcing its safe-haven status.
Meanwhile, Ford's stock slid to its lowest level since early 2021 despite an earnings beat. Its weak 2025 outlook and projected $5 billion to $5.5 billion EV losses raised fresh concerns about profitability and competition in the electric vehicle market.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/02/43573186/china-tech-etfs-surge-as-deepseek-led-ai-boom-fuels-bull-market">China Tech ETFs Surge As DeepSeek-Led AI Boom Fuels Bull Market</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

AMZN

GOOGL

NERD

PLTR

PLTU

PSIL

RBLX

SIXG

TTWO

5 ETFs That Beat Market Turmoil With Gains Last Week

Evercore ISI Group analyst Steve Sakwa maintains Mid-America Apartment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>) with a In-Line and raises the price target from $155 to $159.

Evercore ISI Group Maintains In-Line on Mid-America Apartment, Raises Price Target to $159

DA Davidson analyst Brian Holland maintains Flowers Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>) with a Neutral and lowers the price target from $24 to $21.

DA Davidson Maintains Neutral on Flowers Foods, Lowers Price Target to $21

Evercore ISI Group analyst Chris McNally maintains Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a In-Line and lowers the price target from $125 to $110.

Evercore ISI Group Maintains In-Line on Lear, Lowers Price Target to $110

Evercore ISI Group analyst Omar Saad maintains Canada Goose Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) with a In-Line and lowers the price target from $13 to $10.

GOOS

Evercore ISI Group Maintains In-Line on Canada Goose Hldgs, Lowers Price Target to $10

Deep-pocketed investors have adopted a bullish approach towards First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FSLR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for First Solar. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 40% bearish. Among these notable options, 6 are puts, totaling $354,030, and 4 are calls, amounting to $304,231.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $300.0 for First Solar during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for First Solar's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across First Solar's significant trades, within a strike price range of $130.0 to $300.0, over the past month.
<h3>First Solar Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739203233_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/14/25</td>
<td>$1.49</td>
<td>$0.49</td>
<td>$1.0</td>
<td>$180.00</td>
<td>$200.0K</td>
<td>1.1K</td>
<td align="right">1</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.45</td>
<td>$8.15</td>
<td>$8.45</td>
<td>$160.00</td>
<td>$84.4K</td>
<td>2.9K</td>
<td align="right">110</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$17.0</td>
<td>$16.2</td>
<td>$16.2</td>
<td>$175.00</td>
<td>$81.0K</td>
<td>2.2K</td>
<td align="right">50</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$13.6</td>
<td>$13.2</td>
<td>$13.35</td>
<td>$170.00</td>
<td>$61.4K</td>
<td>1.5K</td>
<td align="right">58</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$16.1</td>
<td>$15.95</td>
<td>$16.1</td>
<td>$175.00</td>
<td>$56.3K</td>
<td>2.2K</td>
<td align="right">86</td>
</tr>
</tbody>
</table>

<h3>About First Solar</h3>
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
<h3>Current Position of First Solar</h3>
<ul>
<li>Currently trading with a volume of 426,819, the FSLR's price is down by -0.58%, now at $167.37. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 15 days.</li>
</ul>
<h3>Professional Analyst Ratings for First Solar</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $279.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on First Solar, maintaining a target price of $236. 
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $335. 
&#x2A; An analyst from Barclays persists with their Overweight rating on First Solar, maintaining a target price of $273. 
&#x2A; In a positive move, an analyst from Seaport Global has upgraded their rating to Buy and adjusted the price target to $274. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest First Solar options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

FSLR

First Solar's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bearish stance on Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with OXY, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for Occidental Petroleum.
This isn't normal.
The overall sentiment of these big-money traders is split between 9% bullish and 72%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $33,450, and 10, calls, for a total amount of $422,360.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $70.0 for Occidental Petroleum over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Occidental Petroleum's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Occidental Petroleum's substantial trades, within a strike price spectrum from $50.0 to $70.0 over the preceding 30 days.
<h3>Occidental Petroleum Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739203228_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.45</td>
<td>$7.1</td>
<td>$7.23</td>
<td>$50.00</td>
<td>$72.3K</td>
<td>3.4K</td>
<td>103</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.36</td>
<td>$2.31</td>
<td>$2.31</td>
<td>$50.00</td>
<td>$46.2K</td>
<td>10.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.39</td>
<td>$2.26</td>
<td>$2.26</td>
<td>$50.00</td>
<td>$45.1K</td>
<td>10.4K</td>
<td>210</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.3</td>
<td>$2.25</td>
<td>$2.25</td>
<td>$50.00</td>
<td>$45.0K</td>
<td>10.4K</td>
<td>612</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$2.28</td>
<td>$2.23</td>
<td>$2.24</td>
<td>$50.00</td>
<td>$44.8K</td>
<td>10.4K</td>
<td>613</td>
</tr>
</tbody>
</table>

<h3>About Occidental Petroleum</h3>
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1,234 thousand barrels of oil equivalent per day in 2023 at a ratio of roughly 50% oil and natural gas liquids and 50% natural gas.
<h3>Where Is Occidental Petroleum Standing Right Now?</h3>
<ul>
<li>With a volume of 2,633,164, the price of OXY is up 2.33% at $47.87. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>What The Experts Say On Occidental Petroleum</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $51.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Truist Securities has decided to maintain their Hold rating on Occidental Petroleum, which currently sits at a price target of $58. 
&#x2A; An analyst from Goldman Sachs has revised its rating downward to Sell, adjusting the price target to $45. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Occidental Petroleum with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Occidental Petroleum's Options Frenzy: What You Need to Know

Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GILD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Gilead Sciences. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 55% bearish. Among these notable options, 6 are puts, totaling $182,719, and 3 are calls, amounting to $98,565.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $80.0 and $105.0 for Gilead Sciences, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Gilead Sciences's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Gilead Sciences's significant trades, within a strike price range of $80.0 to $105.0, over the past month.
<h3>Gilead Sciences Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739203222_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.3</td>
<td>$9.1</td>
<td>$9.1</td>
<td>$92.50</td>
<td>$35.4K</td>
<td>203</td>
<td>49</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/14/25</td>
<td>$0.92</td>
<td>$0.63</td>
<td>$0.8</td>
<td>$91.00</td>
<td>$34.8K</td>
<td>14</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$22.05</td>
<td>$21.95</td>
<td>$22.05</td>
<td>$80.00</td>
<td>$33.0K</td>
<td>126</td>
<td>15</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/14/25</td>
<td>$8.25</td>
<td>$7.5</td>
<td>$8.1</td>
<td>$102.00</td>
<td>$32.4K</td>
<td>1.3K</td>
<td>82</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/14/25</td>
<td>$7.75</td>
<td>$7.2</td>
<td>$7.75</td>
<td>$102.00</td>
<td>$31.0K</td>
<td>1.3K</td>
<td>460</td>
</tr>
</tbody>
</table>

<h3>About Gilead Sciences</h3>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Gilead Sciences</h3>
<ul>
<li>Currently trading with a volume of 1,766,908, the GILD's price is down by -0.86%, now at $95.21. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>What Analysts Are Saying About Gilead Sciences</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $99.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Gilead Sciences, targeting a price of $115. 
&#x2A; An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $84. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Gilead Sciences options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

GILD

Gilead Sciences Options Trading: A Deep Dive into Market Sentiment

WIIM

CTRA

EQNR

SLNG

Shares of oil and gas companies are trading higher. Traders may be evaluating amid ongoing global trade war concerns, which has driven volatility in commodity prices.

Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 13.26%. Currently, Cummins has a market capitalization of $51.01 billion. 
Buying $1000 In CMI: If an investor had bought $1000 of CMI stock 15 years ago, it would be worth $6,471.46 today based on a price of $371.86 for CMI at the time of writing.
<h3>Cummins's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739203211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Evercore ISI Group analyst Chris McNally maintains Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) with a In-Line and lowers the price target from $11 to $10.

Evercore ISI Group Maintains In-Line on Ford Motor, Lowers Price Target to $10

DA Davidson analyst Brandon Rolle maintains MasterCraft Boat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCFT#NASDAQ">MCFT</a>) with a Neutral and lowers the price target from $23 to $22.

MCFT

DA Davidson Maintains Neutral on MasterCraft Boat Hldgs, Lowers Price Target to $22

Evercore ISI Group analyst Steve Sakwa maintains Essex Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) with a In-Line and raises the price target from $297 to $302.

Evercore ISI Group Maintains In-Line on Essex Property Trust, Raises Price Target to $302

DA Davidson analyst Brian Holland maintains Lancaster Colony (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>) with a Neutral and raises the price target from $192 to $207.

LANC

DA Davidson Maintains Neutral on Lancaster Colony, Raises Price Target to $207

Evercore ISI Group analyst Steve Sakwa maintains Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) with a In-Line and raises the price target from $74 to $76.

Evercore ISI Group Maintains In-Line on Equity Residential, Raises Price Target to $76

Evercore ISI Group analyst Steve Sakwa maintains Camden Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>) with a In-Line and raises the price target from $118 to $127.

Evercore ISI Group Maintains In-Line on Camden Prop Trust, Raises Price Target to $127

DA Davidson analyst Gil Luria maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Buy and raises the price target from $150 to $165.

DDOG

DA Davidson Maintains Buy on Datadog, Raises Price Target to $165

Evercore ISI Group analyst John Pancari maintains Cullen/Frost Bankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFR#NYSE">CFR</a>) with a Underperform and raises the price target from $136 to $144.

Evercore ISI Group Maintains Underperform on Cullen/Frost Bankers, Raises Price Target to $144

Citius Pharma ( ($CTXR) ) has released its Q4 earnings. Here is a breakdown of the information Citius Pharma presented to its investors. Citius Pha...

Citius Pharma Reports 2024 Financial Results and Business Update

Citius Pharmaceuticals GAAP EPS of -$5.97

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which i...

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) shares were under pressure...

Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), announced that it has retained Jefferies (JEF) as its exclusi...

Citius Oncology to explore strategic alternatives

Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR), announced progress in preparations for the commercial la...

Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25

Citius Pharmaceuticals falls as it looks to raise $3M in direct offering

Citius Pharmaceuticals (CTXR) announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of its co...

Citius Pharmaceuticals announces $3M registered direct offering priced ATM

Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR) announced that Lymphir has been assigned a unique, perman...

Citius Pharmaceuticals and Citius Oncology announce J-Code issued for Lymphir

AMTM

ARQT

ARTV

AXSM

CTOR

HSAI

KULR

MSTR

NAMS

NUVL

NVDA

RCKT

RHHBY

RHHVF

SEAT

TLRY

VCSA

WKSP

Screenshot 2024-08-06 at 7.17.40 PM

Biotech

General

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Screenshot 2024-07-24 at 5.43.01 PM

Interview

This Pharma Company Is Preparing To Launch Its Lead Candidate

Screenshot 2024-04-17 at 5.34.28 PM

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

Press Releases

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Offerings

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Stock Split

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Earnings

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Small Cap

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Contracts

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

AN2 Therapeutics

Athira Pharma

Biofrontera

Cara Therapeutics

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Dare Bioscience

Durect

Gelteq

Grace Therapeutics

Impact BioMedical

IGC Pharma

Jaguar Health

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

Lyra Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

Marinus Pharmaceuticals, Inc. - Common Stock

Marinus Pharma

Pulmatrix

Talphera

Traws Pharma

TherapeuticsMD

D. Boral Capital

HC Wainwright & Co.

EF Hutton

월요일(30일) 아침 미국 주식 선물이 하락한 가운데, 오늘 투자자들의 관심을 끌 수 있는 종목은 다음과 같다.
1. 셀 사이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) 
벤징가 프로 데이터에 따르면 셀 사이는 5백만 달러 규모 공모에 대해 1,614만 보통주 가격을 주당 31센트로 책정했다. 주가는 시간외 거래에서 8.6% 하락한 0.55달러를 기록했다.
2. CCSC 테크놀로지 인터내셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) 
CCSC 테크놀로지는 9월 30일 종료된 6개월 동안 70만 달러의 순손실을 기록했고, 전년 동기 순이익은 40만 달러였다. 같은 기간 매출은 전년 동기 대비 22.9% 증가한 920만 달러를 기록했다. 주가는 시간외 거래에서 49.4% 상승한 2.45달러였다.
3. 루나 이노베이션스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) 
루나 이노베이션스는 이사회 멤버인 파멜라 코(Pamela Coe)가 은퇴할 것이라고 발표했다. 주가는 시간외 거래 세션에서 5.5% 하락한 2.05달러에 거래되었다.
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 커버리지</a>를 확인하세요.
4. 시티우스 파마슈티컬스 (NASDAQ:<a href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR)</a> 
시티우스 파마슈티컬스는 9월 30일로 마감된 회계연도에 3,940만 달러(주당 5.97달러)의 순손실을 기록했으며, 전년 동기 순손실은 3,250만 달러(주당 5.57달러)였다. 주가는 시간외 거래 세션에서 1.9% 하락한 1.0207달러를 기록했다.
5. 지니어스 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>)
지니어스 그룹의 상반기 매출은 전년 동기 1,180만 달러에서 490만 달러로 감소했다. 순자산은 2023년 12월 31일 기준 1,970만 달러에서 5,460만 달러로 177% 급증했다. 주가는 시간외 거래 세션에서 11.6% 상승한 0.72달러로 마감했다.
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Citius Pharmaceuticals

뉴스

에 대한 최신 뉴스 Citius Pharmaceuticals (NASDAQ:CTXR) 주식

월요일, 12월 30, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌